{"id":37813,"date":"2013-09-04T12:19:34","date_gmt":"2013-09-04T16:19:34","guid":{"rendered":"http:\/\/www.hedgeco.net\/news\/?p=37813"},"modified":"2013-09-04T12:19:34","modified_gmt":"2013-09-04T16:19:34","slug":"former-dendreon-ceo-and-dendreon-bull-start-new-biotech-hedge-fund","status":"publish","type":"post","link":"https:\/\/hedgeco.net\/news\/09\/2013\/former-dendreon-ceo-and-dendreon-bull-start-new-biotech-hedge-fund.html","title":{"rendered":"Former Dendreon CEO and Dendreon Bull Start New Biotech Hedge Fund"},"content":{"rendered":"<p>Xconomy &#8211; Mitch Gold made a lot of money as the CEO of Dendreon, the Seattle-based cancer drug developer. David Miller made his reputation as an investment analyst with in-depth, bullish reports on the company. Now these two are going to work together on a new Seattle-based biotech hedge fund called\u00a0Alpine BioVentures.<\/p>\n<p>Gold isn\u2019t saying how much of his money he\u2019s putting into Alpine, but it will be \u201ca modestly sized fund\u201d in the \u201cmultiple millions\u201d at the start. Gold says he plans to spend about half his time on the fund, with the other half going toward his cancer immunotherapy startup, Alpine Biosciences. Miller, the president of\u00a0Biotech Stock Research, is stepping back from the company he co-founded in 1999 and will no longer write his independent research reports now that he\u2019s managing money.<\/p>\n<p><a href=\"http:\/\/www.xconomy.com\/seattle\/2013\/09\/03\/former-dendreon-ceo-and-dendreon-bull-start-new-biotech-hedge-fund\/\" target=\"_blank\"><strong>Read Complete Article<\/strong><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Xconomy &#8211; Mitch Gold made a lot of money as the CEO of Dendreon, the Seattle-based cancer drug developer. David Miller made his reputation as an investment analyst with in-depth, bullish reports on the company. Now these two are going [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4,16023],"tags":[],"class_list":["post-37813","post","type-post","status-publish","format-standard","hentry","category-syndicated","category-technology"],"_links":{"self":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/37813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/comments?post=37813"}],"version-history":[{"count":2,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/37813\/revisions"}],"predecessor-version":[{"id":37815,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/posts\/37813\/revisions\/37815"}],"wp:attachment":[{"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/media?parent=37813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/categories?post=37813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/hedgeco.net\/news\/wp-json\/wp\/v2\/tags?post=37813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}